{
  "schema_version": 1,
  "kind": "worked_example_release_review",
  "label": "Worked example. The sponsor, compound, study and case reports are fictional and contain no patient data. Agent outputs are illustrative. This is not a customer run or a hosted evaluation run.",
  "workflow": {
    "title": "IND safety-report triage",
    "sponsor": "A fictional oncology biotech with one open IND",
    "compound": "EX-101, a fictional oral kinase inhibitor",
    "study": "EX-101-001: Phase 1, open-label dose escalation in adults with advanced solid tumors",
    "agent_task": "For each serious adverse event report a site sends, decide whether the event is serious, unexpected and a suspected adverse reaction under 21 CFR 312.32(a), then route it: a 7-day IND safety report, a 15-day IND safety report, or no IND safety report.",
    "human_review": "The drug safety physician signs off every report before it goes to FDA. Cases routed to no IND safety report go to the monthly aggregate review queue.",
    "submission": "Since April 1, 2026, IND safety reports under 21 CFR 312.32(c)(1)(i) go to FDA's Adverse Event Monitoring System (AEMS, formerly FAERS) as E2B(R3) individual case safety reports.",
    "routes": [
      {
        "id": "7-day",
        "label": "7-day IND safety report",
        "when": "Unexpected fatal or life-threatening suspected adverse reaction",
        "deadline": "7 calendar days after the sponsor's initial receipt of the information",
        "citation": "21 CFR 312.32(c)(2)"
      },
      {
        "id": "15-day",
        "label": "15-day IND safety report",
        "when": "Any other serious and unexpected suspected adverse reaction",
        "deadline": "15 calendar days after the sponsor determines that the information qualifies",
        "citation": "21 CFR 312.32(c)(1)(i)"
      },
      {
        "id": "none",
        "label": "No IND safety report",
        "when": "The event is not serious, not unexpected, or not a suspected adverse reaction",
        "deadline": "Periodic reporting, such as the IND annual report. Anticipated SAEs go to aggregate analysis.",
        "citation": "21 CFR 312.33; 312.32(c)(1)(i)(C)"
      }
    ]
  },
  "investigator_brochure": {
    "edition": "Investigator brochure, edition 3 (fictional)",
    "listed_adverse_reactions": [
      { "term": "Diarrhea", "grades": "1-3" },
      { "term": "Nausea", "grades": "1-2" },
      { "term": "Vomiting", "grades": "1-2" },
      { "term": "Fatigue", "grades": "1-2" },
      { "term": "Rash maculo-papular", "grades": "1-2" },
      { "term": "Alanine aminotransferase increased", "grades": "1-2" },
      { "term": "Aspartate aminotransferase increased", "grades": "1-2" },
      { "term": "Neutrophil count decreased", "grades": "1-3" }
    ],
    "grading": "CTCAE v5.0"
  },
  "skills": {
    "baseline": {
      "version": 3,
      "status": "In production",
      "rules": [
        { "id": "seriousness", "text": "Apply the outcomes in 21 CFR 312.32(a), including important medical events. An event is serious if either the investigator or the sponsor considers it serious.", "changed": false },
        { "id": "expectedness", "text": "An event is unexpected if the investigator brochure does not list it at the specificity and severity observed.", "changed": false },
        { "id": "causality", "text": "Treat the event as a suspected adverse reaction unless the report documents another cause.", "changed": false },
        { "id": "routing", "text": "Report every serious suspected adverse reaction within 15 calendar days. Treat every death as a suspected adverse reaction. Report deaths and life-threatening events within 7 calendar days.", "changed": false }
      ]
    },
    "candidate": {
      "version": 4,
      "status": "Proposed",
      "purpose": "Stop filing IND safety reports that do not meet all three criteria.",
      "rules": [
        { "id": "seriousness", "text": "Apply the outcomes in 21 CFR 312.32(a), including important medical events. An event is serious if either the investigator or the sponsor considers it serious.", "changed": false },
        { "id": "expectedness", "text": "An event is expected if the investigator brochure lists an adverse reaction in the same organ system.", "changed": true, "correct": false, "why": "21 CFR 312.32(a) makes an event unexpected when it is not listed at the specificity or severity observed. Its own example: hepatic necrosis is unexpected if the brochure refers only to elevated hepatic enzymes or hepatitis." },
        { "id": "causality", "text": "Use the investigator's causality assessment.", "changed": true, "correct": false, "why": "FDA's December 2025 guidance: the sponsor must report events for which the investigator's assessment is negative for causality but the sponsor's evaluation found evidence to suggest a causal relationship." },
        { "id": "routing", "text": "Report only events that are serious, unexpected and suspected: within 7 calendar days if fatal or life-threatening, otherwise within 15.", "changed": true, "correct": true, "why": "Matches 21 CFR 312.32(c)(1)(i) and (c)(2)." },
        { "id": "anticipated", "text": "Do not report anticipated SAEs, such as death from disease progression, as individual cases. Send them to aggregate review.", "changed": true, "correct": true, "why": "FDA's December 2025 guidance gives death due to progressive disease in an oncology trial as an anticipated SAE that needs aggregate analysis." }
      ]
    }
  },
  "rubric": {
    "points_per_field": 1,
    "weighting": "None. Every field in every case is worth one point.",
    "dimensions": [
      { "id": "seriousness", "field": "serious", "description": "Serious under 21 CFR 312.32(a)" },
      { "id": "expectedness", "field": "unexpected", "description": "Unexpected against the investigator brochure" },
      { "id": "causality", "field": "suspected", "description": "Suspected adverse reaction, by the sponsor's evaluation" },
      { "id": "reporting_route", "field": "route", "description": "7-day, 15-day or no IND safety report" }
    ]
  },
  "cases": [
    {
      "id": "sae-01",
      "event": "Diarrhea, grade 3",
      "tests": "A serious reaction the brochure lists at this grade",
      "report": {
        "received": "2026-09-02",
        "subject": "61-year-old man, metastatic colorectal cancer",
        "dose": "Cohort 3, 150 mg once daily",
        "onset": "Day 15",
        "site_seriousness": "Hospitalization",
        "investigator_causality": "Related",
        "narrative": "Seven or more watery stools a day above baseline from Day 15. Admitted for 3 days of IV fluids and loperamide. Stool culture and C. difficile toxin negative. EX-101 held. Diarrhea resolved by Day 19 and dosing resumed at 100 mg without recurrence."
      },
      "reference": {
        "serious": true, "unexpected": false, "suspected": true, "route": "none",
        "basis": "Expected: the brochure lists diarrhea up to grade 3. An IND safety report needs all three criteria (21 CFR 312.32(c)(1)(i)). Include it in the IND annual report (21 CFR 312.33)."
      },
      "baseline": { "serious": true, "unexpected": false, "suspected": true, "route": "15-day", "rationale": "Serious and related. Every serious suspected adverse reaction is reported within 15 days." },
      "candidate": { "serious": true, "unexpected": false, "suspected": true, "route": "none", "rationale": "Expected: the brochure lists diarrhea. Not reportable." }
    },
    {
      "id": "sae-02",
      "event": "Hepatocellular injury with jaundice",
      "tests": "Severity beyond the brochure listing, and an investigator assessment the evidence contradicts",
      "report": {
        "received": "2026-09-08 (initial), 2026-09-10 (follow-up)",
        "subject": "54-year-old woman, metastatic breast cancer, bone-only disease, no liver metastases",
        "dose": "Cohort 4, 200 mg once daily",
        "onset": "Day 29",
        "site_seriousness": "Life-threatening; hospitalization",
        "investigator_causality": "Not related at the initial report (suspected acute viral hepatitis, serology pending). Not updated at follow-up.",
        "narrative": "Jaundice and fatigue on Day 29. Admitted and EX-101 interrupted. Follow-up: hepatitis A IgM, hepatitis B surface antigen and core IgM, hepatitis C RNA and hepatitis E IgM negative. CMV and EBV PCR negative. Antinuclear and anti-smooth muscle antibodies negative. Doppler ultrasound shows no biliary dilation and patent hepatic vessels. No new concomitant medicines. Acetaminophen not detected. ALT fell to 395 U/L three days after interruption.",
        "labs": [
          { "test": "ALT", "screening": "22 U/L", "event": "612 U/L", "multiple_of_uln": "15.3" },
          { "test": "AST", "screening": "25 U/L", "event": "498 U/L", "multiple_of_uln": "12.5" },
          { "test": "Total bilirubin", "screening": "0.6 mg/dL", "event": "4.1 mg/dL", "multiple_of_uln": "3.4" },
          { "test": "Alkaline phosphatase", "screening": "88 U/L", "event": "162 U/L", "multiple_of_uln": "1.3" },
          { "test": "INR", "screening": "1.0", "event": "1.9", "multiple_of_uln": null }
        ],
        "upper_limits_of_normal": "ALT 40 U/L, AST 40 U/L, total bilirubin 1.2 mg/dL, alkaline phosphatase 125 U/L"
      },
      "reference": {
        "serious": true, "unexpected": true, "suspected": true, "route": "7-day",
        "basis": "Unexpected by severity: the brochure lists aminotransferase increases to grade 2 only (21 CFR 312.32(a)). Suspected: hepatic injury is informative as a single case, and no other cause was found (21 CFR 312.32(c)(1)(i)(A)). It is a potential Hy's Law case under FDA's DILI guidance: aminotransferases above 3 × ULN, bilirubin above 2 × ULN, no initial cholestasis and no other cause found. The sponsor must report even though the investigator assessed it as not related. Life-threatening, so the deadline is 7 calendar days from initial receipt (21 CFR 312.32(c)(2))."
      },
      "baseline": { "serious": true, "unexpected": true, "suspected": true, "route": "7-day", "rationale": "Life-threatening. Not listed at this severity: the brochure lists aminotransferase increases to grade 2. The suspected viral cause was excluded on follow-up." },
      "candidate": { "serious": true, "unexpected": false, "suspected": false, "route": "none", "rationale": "Expected: the brochure lists ALT increased and AST increased, which are liver events. Not suspected: the investigator assessed the event as not related." },
      "clock": { "starts": "2026-09-08", "basis": "Sponsor's initial receipt of the information", "due": "2026-09-15" }
    },
    {
      "id": "sae-03",
      "event": "Death due to disease progression",
      "tests": "An anticipated SAE that needs aggregate analysis, not an individual report",
      "report": {
        "received": "2026-09-12",
        "subject": "67-year-old man, metastatic pancreatic cancer",
        "dose": "Cohort 2, 100 mg once daily",
        "onset": "Day 41",
        "site_seriousness": "Death",
        "investigator_causality": "Not related (progressive disease)",
        "narrative": "CT on Day 35 showed new liver and peritoneal metastases and ascites, progressive disease by RECIST 1.1. EX-101 discontinued on Day 36. The patient entered hospice care and died on Day 41. No autopsy. No preceding adverse events above grade 2."
      },
      "reference": {
        "serious": true, "unexpected": true, "suspected": false, "route": "none",
        "basis": "Unexpected because the brochure does not list it, but anticipated. FDA's December 2025 guidance names death due to progressive disease in an oncology trial as an example. Track it for aggregate analysis (21 CFR 312.32(c)(1)(i)(C))."
      },
      "baseline": { "serious": true, "unexpected": true, "suspected": true, "route": "7-day", "rationale": "Death. Every death is treated as a suspected adverse reaction and reported within 7 days." },
      "candidate": { "serious": true, "unexpected": true, "suspected": false, "route": "none", "rationale": "Anticipated SAE: death from disease progression. Sent to aggregate review." }
    },
    {
      "id": "sae-04",
      "event": "Femoral neck fracture after a fall",
      "tests": "A serious, unexpected event with an established alternative cause",
      "report": {
        "received": "2026-09-15",
        "subject": "72-year-old woman, metastatic non-small cell lung cancer",
        "dose": "Cohort 3, 150 mg once daily",
        "onset": "Day 52",
        "site_seriousness": "Hospitalization",
        "investigator_causality": "Not related (mechanical fall)",
        "narrative": "Slipped on a wet floor at home and fell onto her right hip. No dizziness, syncope or palpitations before the fall. Blood pressure and ECG normal on arrival. X-ray showed a displaced femoral neck fracture with no lytic lesion. Admitted for hemiarthroplasty."
      },
      "reference": {
        "serious": true, "unexpected": true, "suspected": false, "route": "none",
        "basis": "A mechanical fall explains the event. No evidence suggests a causal relationship with the drug (21 CFR 312.32(a))."
      },
      "baseline": { "serious": true, "unexpected": true, "suspected": false, "route": "none", "rationale": "The report documents another cause: a mechanical fall." },
      "candidate": { "serious": true, "unexpected": true, "suspected": false, "route": "none", "rationale": "Investigator assessed the event as not related." }
    },
    {
      "id": "sae-05",
      "event": "Pneumonitis, grade 3",
      "tests": "A serious, unexpected suspected reaction that is not fatal or life-threatening",
      "report": {
        "received": "2026-09-18",
        "subject": "59-year-old man, metastatic cholangiocarcinoma",
        "dose": "Cohort 4, 200 mg once daily",
        "onset": "Day 34",
        "site_seriousness": "Hospitalization",
        "investigator_causality": "Possibly related",
        "narrative": "Progressive dyspnea and dry cough. Oxygen saturation 88% on room air. CT chest shows new bilateral ground-glass opacities. Respiratory viral panel, blood cultures and Pneumocystis PCR negative. No prior thoracic radiation or immune checkpoint inhibitor. EX-101 stopped. Improved on prednisone 1 mg/kg."
      },
      "reference": {
        "serious": true, "unexpected": true, "suspected": true, "route": "15-day",
        "basis": "Not listed in the brochure. Infection excluded, no other cause, onset on treatment. Not fatal or life-threatening, so the deadline is 15 calendar days (21 CFR 312.32(c)(1)(i))."
      },
      "baseline": { "serious": true, "unexpected": true, "suspected": true, "route": "15-day", "rationale": "Serious, not listed, no other cause documented." },
      "candidate": { "serious": true, "unexpected": true, "suspected": true, "route": "15-day", "rationale": "Serious, no lung events in the brochure, investigator assessed possibly related." }
    },
    {
      "id": "sae-06",
      "event": "Rash maculo-papular, grade 2",
      "tests": "A non-serious, listed reaction",
      "report": {
        "received": "2026-09-19",
        "subject": "46-year-old woman, metastatic gastric cancer",
        "dose": "Cohort 2, 100 mg once daily",
        "onset": "Day 9",
        "site_seriousness": "None. Reported as an adverse event of special interest under the protocol.",
        "investigator_causality": "Related",
        "narrative": "Maculo-papular rash on the trunk and arms covering about 20% of body surface area. Treated as an outpatient with topical corticosteroids. EX-101 continued at the same dose. No mucosal involvement, blistering or fever."
      },
      "reference": {
        "serious": false, "unexpected": false, "suspected": true, "route": "none",
        "basis": "No seriousness criterion met, and the brochure lists this rash at grade 2."
      },
      "baseline": { "serious": false, "unexpected": false, "suspected": true, "route": "none", "rationale": "Not serious." },
      "candidate": { "serious": false, "unexpected": false, "suspected": true, "route": "none", "rationale": "Not serious." }
    },
    {
      "id": "sae-07",
      "event": "Generalized tonic-clonic seizure",
      "tests": "Seriousness without hospitalization: an important medical event",
      "report": {
        "received": "2026-09-22",
        "subject": "49-year-old woman, recurrent ovarian cancer",
        "dose": "Cohort 4, 200 mg once daily",
        "onset": "Day 12",
        "site_seriousness": "None ticked. Emergency department visit, discharged the same day.",
        "investigator_causality": "Possibly related",
        "narrative": "First-ever seizure at home, witnessed, about 2 minutes. In the emergency department, sodium 138 mmol/L, glucose 97 mg/dL and calcium normal. Brain MRI shows no metastases. Started on levetiracetam and discharged. No new concomitant medicines."
      },
      "reference": {
        "serious": true, "unexpected": true, "suspected": true, "route": "15-day",
        "basis": "Serious as an important medical event. The regulation names convulsions that do not result in hospitalization as an example (21 CFR 312.32(a)). Suspected: a first seizure is uncommon in this population, and there are no brain metastases, metabolic cause or seizure history (21 CFR 312.32(c)(1)(i)(B))."
      },
      "baseline": { "serious": true, "unexpected": true, "suspected": true, "route": "15-day", "rationale": "Important medical event: a convulsion without hospitalization. Not listed. No other cause documented." },
      "candidate": { "serious": true, "unexpected": true, "suspected": true, "route": "15-day", "rationale": "Important medical event. No nervous system events in the brochure. Investigator assessed possibly related." }
    },
    {
      "id": "sae-08",
      "event": "Anaphylaxis",
      "tests": "A life-threatening reaction that is informative as a single case",
      "report": {
        "received": "2026-09-24",
        "subject": "63-year-old man, metastatic renal cell carcinoma",
        "dose": "Cohort 5, 300 mg once daily, first dose",
        "onset": "Day 1",
        "site_seriousness": "Life-threatening; hospitalization",
        "investigator_causality": "Related",
        "narrative": "Forty minutes after the first dose: generalized urticaria, lip and tongue swelling, wheeze and blood pressure 72/40 mmHg. Treated with intramuscular epinephrine twice and IV fluids, and admitted overnight. Serum tryptase 31 µg/L at 1 hour. No other new exposure that day."
      },
      "reference": {
        "serious": true, "unexpected": true, "suspected": true, "route": "7-day",
        "basis": "Anaphylaxis is informative as a single case (21 CFR 312.32(c)(1)(i)(A)). Life-threatening, so the deadline is 7 calendar days from initial receipt (21 CFR 312.32(c)(2))."
      },
      "baseline": { "serious": true, "unexpected": true, "suspected": true, "route": "7-day", "rationale": "Life-threatening, not listed, related." },
      "candidate": { "serious": true, "unexpected": true, "suspected": true, "route": "7-day", "rationale": "Life-threatening, no immune events in the brochure, investigator assessed related." }
    },
    {
      "id": "sae-09",
      "event": "Neutrophil count decreased, grade 3",
      "tests": "A listed reaction made serious by prolonging a hospital stay",
      "report": {
        "received": "2026-09-26",
        "subject": "70-year-old man, metastatic cholangiocarcinoma",
        "dose": "Cohort 3, 150 mg once daily",
        "onset": "Day 22",
        "site_seriousness": "Prolonged hospitalization",
        "investigator_causality": "Related",
        "narrative": "Admitted for a planned biliary stent exchange. Admission absolute neutrophil count 0.7 × 10⁹/L. Afebrile throughout. Discharge delayed 2 days for monitoring. EX-101 held. Neutrophils recovered to 1.6 × 10⁹/L by Day 29."
      },
      "reference": {
        "serious": true, "unexpected": false, "suspected": true, "route": "none",
        "basis": "Serious because it prolonged a hospitalization (21 CFR 312.32(a)). Expected: the brochure lists neutrophil count decreased up to grade 3."
      },
      "baseline": { "serious": true, "unexpected": false, "suspected": true, "route": "15-day", "rationale": "Serious and related. Every serious suspected adverse reaction is reported within 15 days." },
      "candidate": { "serious": true, "unexpected": false, "suspected": true, "route": "none", "rationale": "Expected: the brochure lists neutrophil count decreased. Not reportable." }
    },
    {
      "id": "sae-10",
      "event": "ALT and AST increased, grade 2",
      "tests": "A liver event the brochure lists at this grade",
      "report": {
        "received": "2026-09-29",
        "subject": "57-year-old woman, metastatic colorectal cancer",
        "dose": "Cohort 4, 200 mg once daily",
        "onset": "Day 21",
        "site_seriousness": "Hospitalization",
        "investigator_causality": "Related",
        "narrative": "Routine labs: ALT 168 U/L (4.2 × ULN) and AST 150 U/L (3.8 × ULN). Total bilirubin 0.8 mg/dL and alkaline phosphatase normal. No symptoms. Admitted overnight for workup at the investigator's discretion. Viral serologies negative. EX-101 held. ALT 70 U/L (1.8 × ULN) by Day 28."
      },
      "reference": {
        "serious": true, "unexpected": false, "suspected": true, "route": "none",
        "basis": "Expected: the brochure lists ALT and AST increased up to grade 2, and bilirubin stayed normal."
      },
      "baseline": { "serious": true, "unexpected": false, "suspected": true, "route": "15-day", "rationale": "Serious and related. Every serious suspected adverse reaction is reported within 15 days." },
      "candidate": { "serious": true, "unexpected": false, "suspected": true, "route": "none", "rationale": "Expected: the brochure lists ALT and AST increased. Not reportable." }
    }
  ],
  "decision": {
    "decision": "needs_work",
    "created_at": "2026-10-21T16:42:00+00:00",
    "owner": "Drug safety physician (fictional)",
    "notes": "Do not ship v4. It misses the 7-day report on sae-02. Keep the routing rule and the anticipated-SAE rule. Restore expectedness at the specificity and severity in the brochure. Make causality the sponsor's evaluation: consider the investigator's assessment, but do not adopt it. Keep v3 in production until the revision scores 4 of 4 on every case that needs an IND safety report."
  },
  "sources": [
    { "title": "21 CFR 312.32, IND safety reporting", "url": "https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.32" },
    { "title": "Sponsor Responsibilities: Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies (FDA guidance, December 2025)", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sponsor-responsibilities-safety-reporting-requirements-and-safety-assessment-ind-and" },
    { "title": "Drug-Induced Liver Injury: Premarketing Clinical Evaluation (FDA guidance, July 2009)", "url": "https://www.fda.gov/media/116737/download" },
    { "title": "Providing Regulatory Submissions in Electronic Format: IND Safety Reports (FDA guidance, April 2024; required from April 1, 2026)", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-ind-safety-reports-guidance-industry" },
    { "title": "IND Application Reporting: IND Safety Reports (FDA)", "url": "https://www.fda.gov/drugs/investigational-new-drug-application-ind/ind-application-reporting-ind-safety-reports" }
  ]
}
